Skip to main content
. 2023 Nov 15;34:102079. doi: 10.1016/j.omtn.2023.102079

Figure 4.

Figure 4

Systemic administration of CM-miR-143 lipoplexes prolonged CRC pelvic recurrence mouse survival

(A) All IVIS images of control and CM-miR-143 before treatment in the DLD-1 clone#1-Luc and HT-29-Luc mouse models. (B) The relative fluorescence intensity of control (C) and CM-miR-143 (CM-143) before treatment in the DLD-1 clone#1-Luc and HT-29-Luc mouse models. There was no significant difference between the 2 groups. (n = 15) (C) The body weight of control and CM-miR-143 before treatment of the DLD-1 clone#1-Luc and HT-29-Luc mouse models. There was no significant difference in body weight between the 2 groups (n = 15). (D) Kaplan-Meier plots show the survival rate in control (blue line) and CM-miR-143 (orange line) groups in the DLD-1 clone#1-Luc and HT-29-Luc mouse models (n = 15). The significance of survival duration was determined using log rank survival analysis. (E) Body weights did not differ significantly between control and CM-miR-143 groups in either the DLD-1 clone#1-Luc or the HT-29-Luc mouse models after treatment (n = 15). ns, not significant. Data are presented as the mean ± SEM.